Cancer Trials Ireland > Cancer Trials > Genitourinary > PACE-NODES

PACE-NODES

About this trial

The purpose of this study is to test an advanced type of external beam radiotherapy called stereotactic body radiotherapy (also known as SBRT) in 536 participants with high risk localised prostate cancer (that is, prostate cancer that has not spread beyond the prostate gland but is at high risk of growing quickly or spreading). Importantly, this treatment delivers a potentially curative dose of radiotherapy in only 5 treatments over two weeks. Half the participants in the trial will receive radiotherapy to the prostate, the other half will have radiotherapy to the prostate as well as the surrounding lymph nodes. The investigators will follow patients in the trial for at least three and half years to see which treatment is best. The investigators will be looking at whether it is safe to give this treatment by reviewing any side-effects that occur and also assessing whether giving SBRT to the lymph nodes as well as the prostate reduces the chance of prostate cancer returning.

Patient Profile

Patients with high risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy

Where’s this trial being run?

Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre and St Luke’s Radiation Oncology Network @ Beaumont Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: PACE-NODES
Number: 23-01
Full Title:

A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT
Principal Investigator: Dr Paul Kelly
Type: Collaborative
Sponsor:

Cancer Trials Ireland (Sponsor in ROI)
ICR-CTSU (Global Sponsor)
Recruitment Started: Global:
Ireland: January 2024
Global Recruitment Target: 536
Ireland Recruitment Target: 33